792 Results

People

  1. Kemeny
    Kemeny
  2. Kris
    Kris
  3. De Angelis
    De Angelis
  4. Giralt
    Giralt
  5. Usmani
    Usmani
  6. Landau
    Landau
  7. Hassoun
    Hassoun
  8. Yahalom
    Yahalom
  9. Comenzo
    Comenzo
  10. Posner
    Posner

Groups

  1. Department of Medicine (421)
  2. Hematologic Malignancies, Division of (207)
  3. Solid Tumor Oncology Division (206)
  4. Center for Hematologic Malignancies (205)
  5. Survivorship Research (119)
  6. Gastrointestinal Oncology Service (92)
  7. Center for Pancreatic Cancer Research (65)
  8. Surgery (65)
  9. Bone Marrow Transplant (61)
  10. Sloan Kettering Institute Faculty (60)
  1. "dexamethasone"
Formats
  1. Journal Article (719)
  2. Review (25)
  3. Conference Paper (14)
  4. Research Letter (13)
  5. Meeting Abstract (6)
  6. Correspondence (5)
  7. Editorial (5)
  8. Guidelines (4)
  9. Book Section (1)
Groups
  1. Department of Medicine (421)
  2. Hematologic Malignancies, Division of (207)
  3. Solid Tumor Oncology Division (206)
  4. Center for Hematologic Malignancies (205)
  5. Survivorship Research (119)
  6. Gastrointestinal Oncology Service (92)

More Groups

People
  1. Nancy Kemeny (66)
  2. Mark Kris (43)
  3. Lisa De Angelis (33)
  4. Saad Usmani (32)
  5. Sergio Giralt (32)
  6. Heather Landau (27)

More People

Years
  1. 2025 (23)
  2. 2024 (48)
  3. 2023 (34)
  4. 2022 (23)
  5. 2021 (9)
  6. 2020 (20)

More Years

Publications
  1. Journal of Clinical Oncology (56)
  2. Journal of the National Comprehensive Cancer Network (31)
  3. Cancer (27)
  4. Blood (23)
  5. Seminars in Oncology (21)
  6. British Journal of Haematology (18)

More Publications

Publishers
  1. Elsevier Inc. (130)
  2. American Society of Clinical Oncology (59)
  3. Lippincott Williams & Wilkins (48)
  4. Springer (44)
  5. Wiley Blackwell (44)
  6. Nature Publishing Group (43)

More Publishers

Results (792)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Progression-free survival of daratumumab versus bortezomib triplet combination with lenalidomide and dexamethasone in transplant ineligible patients with newly diagnosed multiple myeloma: TAURUS chart review study
    Journal Article

    Gordan, L. N.; Tan, C. R.; Vescio, R.; Ye, J. C.; Schinke, C.; Medhekar, R.; Fu, A. Z.; Lafeuille, M. H.; Thompson-Leduc, P.; Khare, V.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Cross fire: Daratumumab-based therapies are standard of care in newly diagnosed multiple myeloma
    Review

    Korde, N.; Usmani, S. Z.
    Hematology-Oncology and Stem Cell Therapy (2023)

    Fulltext@MSK | Save
  • Diabetes care in the oncologic population
    Journal Article

    Presswala, L. S.; Farooki, A.; Flory, J.
    Contemporary Endocrinology (2023)

    Fulltext@MSK | Save
  • Oral selinexor as maintenance therapy after first-line chemotherapy for advanced or recurrent endometrial cancer
    Journal Article

    Vergote, I.; Perez-Fidalgo, J. A.; Hamilton, E. P.; Valabrega, G.; Van Gorp, T.; Sehouli, J.; Cibula, D.; Levy, T.; Welch, S.; Richardson, D. L.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Genomic and immune signatures predict clinical outcome in newly diagnosed multiple myeloma treated with immunotherapy regimens
    Journal Article

    Maura, F.; Boyle, E. M.; Coffey, D.; Maclachlan, K.; Gagler, D.; Diamond, B.; Ghamlouch, H.; Blaney, P.; Ziccheddu, B.; Cirrincione, A.; more...
    Nature Cancer (2023)

    Fulltext@MSK | Save
  • Mature T-cell and NK-cell lymphoma involvement of the central nervous system: A single center experience
    Journal Article

    Ma, H.; Marchi, E.; O’Connor, O. A.; Lue, J. K.
    Leukemia and Lymphoma (2023)

    Fulltext@MSK | Save
  • Polyclonal immunoglobulin recovery in patients with newly diagnosed myeloma receiving maintenance therapy after autologous haematopoietic stem cell transplantation with either carfilzomib, lenalidomide and dexamethasone or lenalidomide alone: Subanalysis of the randomized phase 3 ATLAS trial
    Journal Article

    Kubicki, T.; Dytfeld, D.; Wróbel, T.; Jamroziak, K.; Robak, P.; Czyż, J.; Tyczyńska, A.; Druzd-Sitek, A.; Giannopoulos, K.; Szczepaniak, T.; more...
    British Journal of Haematology (2023)

    Fulltext@MSK | Save
  • Safety of immunomodulatory systemic therapies used in the management of immune-related cutaneous adverse events
    Review

    Gu, S. L.; Nath, S.; Markova, A.
    Pharmaceuticals (2023)

    Fulltext@MSK | Save
  • Randomized phase II trial of dendritic cell/myeloma fusion vaccine with lenalidomide maintenance after upfront autologous hematopoietic cell transplantation for multiple myeloma: BMT CTN 1401
    Journal Article

    Chung, D. J.; Shah, N.; Wu, J.; Logan, B.; Bisharat, L.; Callander, N.; Cheloni, G.; Anderson, K.; Chodon, T.; Dhakal, B.; more...
    Clinical Cancer Research (2023)

    Fulltext@MSK | Save
  • Expert consensus on the incorporation of anti-CD38 monoclonal antibody therapy into the management of newly diagnosed multiple myeloma
    Review

    Lonial, S.; Bowser, A. D.; Chari, A.; Costello, C.; Krishnan, A.; Usmani, S. Z.
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save